clinical trial · NCT05338476
A Study of Effects of Selpercatinib (LY3527723) on Midazolam in Healthy Participants
Eli Lilly and Company·phase1·completed·n = 16
HealthyMidazolamSelpercatinib
brief summary
The main purpose of this study is to assess the effect of selpercatinib on how fast midazolam gets into the blood stream and how long it takes the body to remove it when administered in healthy participants. Information about safety and tolerability will be collected. The study will last up to about 6 weeks, inclusive of screening period.
started
Jul 12, 2018
primary completion
Aug 1, 2018
completion
Sep 18, 2018
last updated
Oct 20, 2025
official title
An Open-Label, Fixed-Sequence Study to Evaluate the Effect of Multiple Doses of LOXO-292 on the Single Dose Pharmacokinetics of Midazolam in Healthy Adult Subjects
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol